EUS-guided FNA of pancreatic metastases

A multicenter experience

John DeWitt, Paul Jowell, Julia LeBlanc, Lee McHenry, Kathleen McGreevy, Harvey Cramer, Keith Volmar, Stuart Sherman, Frank Gress

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Background: Metastatic lesions of the pancreas are a rare but important cause of focal pancreatic lesions. The purpose of this study is to describe the EUS features, cytologic diagnoses, and clinical impact of a cohort of patients with pancreatic metastases diagnosed by EUS-guided FNA (EUS-FNA). Methods: Over a 6-year period, in a retrospective, multicenter study, patients had the diagnosis of pancreatic metastases confirmed with EUS-FNA. All examinations were performed by one of 5 experienced endosonographers. The EUS and the clinical findings of pancreatic metastases were compared with those of a cohort with primary pancreatic malignancy. Results: Thirty-seven patients with possible metastases were identified, and 13 were excluded because of diagnostic uncertainty. The remaining 24 underwent EUS-FNA (mean passes 4.1) of a pancreatic mass without complications. Diagnoses included metastases from primary kidney (10), skin (6), lung (4), colon (2), liver (1), and stomach (1) cancer. In 4 (17%), 16 (67%), and 24 (100%) patients, EUS-FNA provided the initial diagnosis of malignancy, tumor recurrence, and pancreatic metastases, respectively. Four (17%) metastases initially were discovered by EUS after negative (n = 3) or inconclusive (n = 1) CT scans. Compared with primary cancer, pancreatic metastases were more likely to have well-defined margins (46% vs. 4%) compared with irregular (94% vs. 54%; p < 0.0001) margins. No statistically significant difference between the two populations was noted for tumor size, echogenicity, consistency, location, lesion number, or number of FNA passes performed. Conclusions: Pancreatic metastases are an important cause of focal pancreatic lesions and may occasionally be discovered during EUS examination after previously negative or inconclusive CT. Use of immunocytochemistry, when available, may help to confirm a suspected diagnosis. These lesions are more likely to have well-defined EUS margins compared with primary pancreatic cancer.

Original languageEnglish
Pages (from-to)689-696
Number of pages8
JournalGastrointestinal Endoscopy
Volume61
Issue number6
DOIs
StatePublished - Jun 2005

Fingerprint

Endoscopic Ultrasound-Guided Fine Needle Aspiration
Neoplasm Metastasis
Pancreatic Neoplasms
Neoplasms
Multicenter Studies
Stomach Neoplasms
Uncertainty
Pancreas
Colon
Retrospective Studies
Immunohistochemistry
Kidney
Recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

EUS-guided FNA of pancreatic metastases : A multicenter experience. / DeWitt, John; Jowell, Paul; LeBlanc, Julia; McHenry, Lee; McGreevy, Kathleen; Cramer, Harvey; Volmar, Keith; Sherman, Stuart; Gress, Frank.

In: Gastrointestinal Endoscopy, Vol. 61, No. 6, 06.2005, p. 689-696.

Research output: Contribution to journalArticle

DeWitt, John ; Jowell, Paul ; LeBlanc, Julia ; McHenry, Lee ; McGreevy, Kathleen ; Cramer, Harvey ; Volmar, Keith ; Sherman, Stuart ; Gress, Frank. / EUS-guided FNA of pancreatic metastases : A multicenter experience. In: Gastrointestinal Endoscopy. 2005 ; Vol. 61, No. 6. pp. 689-696.
@article{0e2b37db68354f0692cd26864aae23e0,
title = "EUS-guided FNA of pancreatic metastases: A multicenter experience",
abstract = "Background: Metastatic lesions of the pancreas are a rare but important cause of focal pancreatic lesions. The purpose of this study is to describe the EUS features, cytologic diagnoses, and clinical impact of a cohort of patients with pancreatic metastases diagnosed by EUS-guided FNA (EUS-FNA). Methods: Over a 6-year period, in a retrospective, multicenter study, patients had the diagnosis of pancreatic metastases confirmed with EUS-FNA. All examinations were performed by one of 5 experienced endosonographers. The EUS and the clinical findings of pancreatic metastases were compared with those of a cohort with primary pancreatic malignancy. Results: Thirty-seven patients with possible metastases were identified, and 13 were excluded because of diagnostic uncertainty. The remaining 24 underwent EUS-FNA (mean passes 4.1) of a pancreatic mass without complications. Diagnoses included metastases from primary kidney (10), skin (6), lung (4), colon (2), liver (1), and stomach (1) cancer. In 4 (17{\%}), 16 (67{\%}), and 24 (100{\%}) patients, EUS-FNA provided the initial diagnosis of malignancy, tumor recurrence, and pancreatic metastases, respectively. Four (17{\%}) metastases initially were discovered by EUS after negative (n = 3) or inconclusive (n = 1) CT scans. Compared with primary cancer, pancreatic metastases were more likely to have well-defined margins (46{\%} vs. 4{\%}) compared with irregular (94{\%} vs. 54{\%}; p < 0.0001) margins. No statistically significant difference between the two populations was noted for tumor size, echogenicity, consistency, location, lesion number, or number of FNA passes performed. Conclusions: Pancreatic metastases are an important cause of focal pancreatic lesions and may occasionally be discovered during EUS examination after previously negative or inconclusive CT. Use of immunocytochemistry, when available, may help to confirm a suspected diagnosis. These lesions are more likely to have well-defined EUS margins compared with primary pancreatic cancer.",
author = "John DeWitt and Paul Jowell and Julia LeBlanc and Lee McHenry and Kathleen McGreevy and Harvey Cramer and Keith Volmar and Stuart Sherman and Frank Gress",
year = "2005",
month = "6",
doi = "10.1016/S0016-5107(05)00287-7",
language = "English",
volume = "61",
pages = "689--696",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - EUS-guided FNA of pancreatic metastases

T2 - A multicenter experience

AU - DeWitt, John

AU - Jowell, Paul

AU - LeBlanc, Julia

AU - McHenry, Lee

AU - McGreevy, Kathleen

AU - Cramer, Harvey

AU - Volmar, Keith

AU - Sherman, Stuart

AU - Gress, Frank

PY - 2005/6

Y1 - 2005/6

N2 - Background: Metastatic lesions of the pancreas are a rare but important cause of focal pancreatic lesions. The purpose of this study is to describe the EUS features, cytologic diagnoses, and clinical impact of a cohort of patients with pancreatic metastases diagnosed by EUS-guided FNA (EUS-FNA). Methods: Over a 6-year period, in a retrospective, multicenter study, patients had the diagnosis of pancreatic metastases confirmed with EUS-FNA. All examinations were performed by one of 5 experienced endosonographers. The EUS and the clinical findings of pancreatic metastases were compared with those of a cohort with primary pancreatic malignancy. Results: Thirty-seven patients with possible metastases were identified, and 13 were excluded because of diagnostic uncertainty. The remaining 24 underwent EUS-FNA (mean passes 4.1) of a pancreatic mass without complications. Diagnoses included metastases from primary kidney (10), skin (6), lung (4), colon (2), liver (1), and stomach (1) cancer. In 4 (17%), 16 (67%), and 24 (100%) patients, EUS-FNA provided the initial diagnosis of malignancy, tumor recurrence, and pancreatic metastases, respectively. Four (17%) metastases initially were discovered by EUS after negative (n = 3) or inconclusive (n = 1) CT scans. Compared with primary cancer, pancreatic metastases were more likely to have well-defined margins (46% vs. 4%) compared with irregular (94% vs. 54%; p < 0.0001) margins. No statistically significant difference between the two populations was noted for tumor size, echogenicity, consistency, location, lesion number, or number of FNA passes performed. Conclusions: Pancreatic metastases are an important cause of focal pancreatic lesions and may occasionally be discovered during EUS examination after previously negative or inconclusive CT. Use of immunocytochemistry, when available, may help to confirm a suspected diagnosis. These lesions are more likely to have well-defined EUS margins compared with primary pancreatic cancer.

AB - Background: Metastatic lesions of the pancreas are a rare but important cause of focal pancreatic lesions. The purpose of this study is to describe the EUS features, cytologic diagnoses, and clinical impact of a cohort of patients with pancreatic metastases diagnosed by EUS-guided FNA (EUS-FNA). Methods: Over a 6-year period, in a retrospective, multicenter study, patients had the diagnosis of pancreatic metastases confirmed with EUS-FNA. All examinations were performed by one of 5 experienced endosonographers. The EUS and the clinical findings of pancreatic metastases were compared with those of a cohort with primary pancreatic malignancy. Results: Thirty-seven patients with possible metastases were identified, and 13 were excluded because of diagnostic uncertainty. The remaining 24 underwent EUS-FNA (mean passes 4.1) of a pancreatic mass without complications. Diagnoses included metastases from primary kidney (10), skin (6), lung (4), colon (2), liver (1), and stomach (1) cancer. In 4 (17%), 16 (67%), and 24 (100%) patients, EUS-FNA provided the initial diagnosis of malignancy, tumor recurrence, and pancreatic metastases, respectively. Four (17%) metastases initially were discovered by EUS after negative (n = 3) or inconclusive (n = 1) CT scans. Compared with primary cancer, pancreatic metastases were more likely to have well-defined margins (46% vs. 4%) compared with irregular (94% vs. 54%; p < 0.0001) margins. No statistically significant difference between the two populations was noted for tumor size, echogenicity, consistency, location, lesion number, or number of FNA passes performed. Conclusions: Pancreatic metastases are an important cause of focal pancreatic lesions and may occasionally be discovered during EUS examination after previously negative or inconclusive CT. Use of immunocytochemistry, when available, may help to confirm a suspected diagnosis. These lesions are more likely to have well-defined EUS margins compared with primary pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=18044386162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044386162&partnerID=8YFLogxK

U2 - 10.1016/S0016-5107(05)00287-7

DO - 10.1016/S0016-5107(05)00287-7

M3 - Article

VL - 61

SP - 689

EP - 696

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 6

ER -